CellCept 250 Special Drug Use Surveillance, Lupus nephritis

CellCept 250 Special Drug Use Surveillance, Lupus nephritis - CellCept 250 Special Drug Use Surveillance, Lupus nephritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027397

Enrollment

550

Registered

2017-06-05

Start date

2017-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus nephritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The naive patients for Celcept,after diagnosed as SLE and LN on the basis of the ACR's criterion

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Adverse reaction incidence Rate of achieving for the treatment by evaluation items eGFR, etc.	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co. Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results